Prevalence of the NKG2D Thr72Ala polymorphism in patients with cervical carcinoma

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 8, 2012, Pages 841-845

  Roszak, Andrzej ^a,b   Lianeri, Margarita ^b   Jagodziński, Paweł P ^b  

^a GREATER POLAND CANCER CENTER   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2D;

ADULT; ARTICLE; CANCER GROWTH; CANCER STAGING; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLAND; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SQUAMOUS CELL; UTERINE CERVIX CARCINOMA; UTERUS CARCINOMA;

ADULT; ALANINE; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA PRIMERS; FEMALE; HUMANS; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; THREONINE; UTERINE CERVICAL NEOPLASMS;

EID: 84865687381     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0308     Document Type: Article

References (42)

1. Arbyn M, Raifu AO, Autier P, Ferlay J (2007) Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 18:1708-1715.
2. Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, et al. (2008) Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer 8:16.
3. Bacon L, Eagle RA, Meyer M, et al. (2004) Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol 173:1078-1084.
4. Bahram S, Bresnahan M, Geraghty DE, Spies T. (1994) A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 91:6259-6263.
5. Carbone E, Neri P, Mesuraca M, et al. (2005) HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105:251-258.
6. Castellsague X, Munoz N. (2003) Chapter 3: cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer InstMonogr 31:20-28.
7. Chalupny NJ, Sutherland CL, Lawrence WA, et al. (2003) ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun 305:129-135.
8. Cosman D, Müllberg J, Sutherland CL, et al. (2001) ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123-133.
9. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-171.
10. Frazer I. (2007) Correlating immunity with protection for HPV infection. Int J Infect Dis 11:S10-S16.
11. Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, et al. (2009) Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 9:186.
12. Garrity D, Call ME, Feng J, Wucherpfennig KW. (2005) The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexamericstructure. Proc Natl Acad Sci USA 102:7641-7646.
13. Giuliano AR, Harris R, Sedjo RL, et al. (2002) Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. J Infect Dis 186:462-469.
14. Groh V, Wu J, Yee C, Spies T. (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738.
15. Hasan UA, Bates E, Takeshita F, et al. (2007) TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178:3186-3197.
16. Hayashi T, Imai K, Morishita Y, et al. (2006) Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Cancer Res 66:563-570.
17. Holdenrieder S, Stieber P, Peterfi A, et al. (2006) Soluble MICA in malignant diseases. Int J Cancer 118:684-687.
18. Houchins JP, Yabe T, McSherry C, Bach FH. (1991) DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med 173:1017-1020.
19. Hyka-Nouspikel N, Lucian L, Murphy E, et al. (2007) DAP10 deficiency breaks the immune tolerance against transplantable syngeneic melanoma. J Immunol 179:3763-3771.
20. Hyka-Nouspikel N, Phillips JH. (2006) Physiological roles of murine DAP10 adapter protein in tumor immunity and autoimmunity. Immunol Rev 214:106-117.
21. Jinushi M, Takehara T, Tatsumi T, et al. (2005) Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 43:1013-1020.
22. Kabalak G, Thomas RM, Martin J, et al. (2010) Association of an NKG2D gene variant with systemic lupus erythematosus in two populations. Hum Immunol 71:74-78.
23. Kobayashi A, Greenblatt RM, Anastos K, et al. (2004) Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 64:6766-6774.
24. Lanier LL. (2008) Evolutionary struggles between NK cells and viruses. Nat Rev Immunol 8:259-268.
25. Lee JC, Lee KM, Ahn YO, et al. (2011) A possible mechanism of impaired NK cytotoxicity in cancer patients: down-regulation of DAP10 by TGF-beta1. Tumori 97:350-357.
26. Magnusson PK, Lichtenstein P, Gyllensten UB. (2000) Heritability of cervical tumours. Int J Cancer 88:698-701.
27. Manickam A. Sivanandham M. Tourkova IL. (2007) Immunological role of dendritic cells in cervical cancer. Adv Exp Med Biol 601:155-162.
28. Moretta L, Bottino C, Pende D, et al. (2006) Surface NK receptors and their ligands on tumor cells. Semin Immunol 18:151-158.
29. Muñoz N, Bosch FX, de Sanjosé S, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527.
30. Pende D, Parolini S, Pessino A, et al. (1999) Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 190:1505-1516.
31. Pende D, Rivera P, Marcenaro S, Chang CC, et al. (2002) Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2Ddependent natural killer cell cytotoxicity. Cancer Res 62:6178-6186.
32. *02- restricted HPV-16 E7 peptide-specific CD4 +T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res 13:2479-2487.
33. Pessino A, Sivori S, Bottino C, et al. (1998) Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 188:953-960.
34. Raulet DH. (2003) Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3:781-790.
35. Salih HR, Goehlsdorf D, Steinle A. (2006) Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol 67:188-195.
36. Sivori S, Vitale M, Morelli L, et al. (1997) p46, a novel natural killer cell-specific surface molecule which mediates cell activation. J Exp Med 186:1129-1136.
37. Stanley M. (2008) Immunobiology of HPV and HPV vaccines. Gynecol Oncol 109:S15-S21.
38. Textor S, Durst M, Jansen L, et al. (2008) Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 123:2343-2353.
39. Walboomers JM, Jacobs MV, Manos MM, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
40. Waldhauer I, Steinle A. (2008) NK cells and cancer immunosurveillance. Oncogene 27:5932-5943.
41. Wira CR, Fahey JV, Sentman CL, et al. (2005) Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev 206:306-335.
42. Wu J, Song Y, Bakker AB, et al. (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730-732.